Obesity in GI Care (Aug. 23rd Session):
Post-Test and Evaluation

Question Title

* 1. In the MERIT trial of endoscopic sleeve gastroplasty (ESG) compared to lifestyle, what percentage of the lost weight was maintained 2 years after ESG?

10%

20%

40%

60%

80%

Question Title

* 2. Which of the following comorbid conditions is an absolute contraindication for the fluid-filled intragastric balloon Orbera?

Past history of renal cancer

Nonalcoholic steatohepatitis with grade 3 liver fibrosis

Prior adjustable gastric band, now loosened

History of cardiac stents with ongoing use of apixaban and aspirin

Question Title

* 3. In the MERIT trial, what percentage of patients needed a surgical intervention for the management of an adverse event?

Question Title

* 4. Which of the following is a contraindication for use of Tirzepatide?

Seizure disorder

Hyperthyroidism

Papillary Thyroid Cancer

Bipolar disorder

Medullary Thyroid Cancer

Question Title

* 5. Degree

NP, PA

PhD

PharmD

Patient

Medical Student

Other

Question Title

* 6. Specialty

Gastroenterology

Hepatology

Primary Care/ Family Medicine

Fellow

Nutrition

Oncology

Immunology

Endoscopy

Other

Surgery

Question Title

* 7. Practice Setting

Academic Medical Center

Community Hospital

Private Practice

In-training

Other

Question Title

* 8. Overall, how would you rate the educational activity?

Question Title

* 9. This activity has met the learning objectives.

Strongly agree

Agree

Neither agree nor disagree

Strongly disagree

Question Title

* 10. Did you perceive any commercial bias in any of the sessions?

Yes

Question Title

* 11. If yes, please specify concern:

Question Title

* 12. As a result of participating in this activity, will you make any changes in your practice or research?

Yes

Question Title

* 13. If yes, what will you do differently?

Question Title

* 14. How will this impact patient care?

Question Title

* 15. What barriers may block you from making this change?

Question Title

* 16. How did you learn about this activity?

AGA Brochure

AGA e-Digest

AGA Website

Gastroenterology

Clinical Gastroenterology and Hepatology

Colleague or Other

Obesity in GI Care (Aug. 23rd Session):
Post-Test and Evaluation

Question Title

* 1. In the MERIT trial of endoscopic sleeve gastroplasty (ESG) compared to lifestyle, what percentage of the lost weight was maintained 2 years after ESG?

Question Title

* 2. Which of the following comorbid conditions is an absolute contraindication for the fluid-filled intragastric balloon Orbera?

Question Title

* 3. In the MERIT trial, what percentage of patients needed a surgical intervention for the management of an adverse event?

Question Title

* 4. Which of the following is a contraindication for use of Tirzepatide?

Question Title

* 5. Degree

Question Title

* 6. Specialty

Question Title

* 7. Practice Setting

Question Title

* 8. Overall, how would you rate the educational activity?

Question Title

* 9. This activity has met the learning objectives.

Question Title

* 10. Did you perceive any commercial bias in any of the sessions?

Question Title

* 11. If yes, please specify concern:

Question Title

* 12. As a result of participating in this activity, will you make any changes in your practice or research?

Question Title

* 13. If yes, what will you do differently?

Question Title

* 14. How will this impact patient care?

Question Title

* 15. What barriers may block you from making this change?

Question Title

* 16. How did you learn about this activity?

Question Title

* 17. If other, please specify

Question Title

* 18. How many patients do you see in this topic area per month?

Question Title

* 19. Please add additional comments/suggestions.

Obesity in GI Care (Aug. 23rd Session): Post-Test and Evaluation

Question Title

* 1. In the MERIT trial of endoscopic sleeve gastroplasty (ESG) compared to lifestyle, what percentage of the lost weight was maintained 2 years after ESG?

Question Title

* 2. Which of the following comorbid conditions is an absolute contraindication for the fluid-filled intragastric balloon Orbera?

Question Title

* 3. In the MERIT trial, what percentage of patients needed a surgical intervention for the management of an adverse event?

Question Title

* 4. Which of the following is a contraindication for use of Tirzepatide?

Question Title

* 5. Degree

Question Title

* 6. Specialty

Question Title

* 7. Practice Setting

Question Title

* 8. Overall, how would you rate the educational activity?

Question Title

* 9. This activity has met the learning objectives.

Question Title

* 10. Did you perceive any commercial bias in any of the sessions?

Question Title

* 11. If yes, please specify concern:

Question Title

* 12. As a result of participating in this activity, will you make any changes in your practice or research?

Question Title

* 13. If yes, what will you do differently?

Question Title

* 14. How will this impact patient care?

Question Title

* 15. What barriers may block you from making this change?

Question Title

* 16. How did you learn about this activity?

Question Title

* 17. If other, please specify

Question Title

* 18. How many patients do you see in this topic area per month?

Question Title

* 19. Please add additional comments/suggestions.

Obesity in GI Care (Aug. 23rd Session):
Post-Test and Evaluation